Beam Therapeutics (MEX:BEAM) Momentum Rank: 4 (As of Sep. 07, 2026) — 33% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:BEAM Beam Therapeutics Inc MEX:BEAM
64 GF Score
Price MXN500.00
GF Value MXN425.92
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Beam Therapeutics Momentum Rank?

Beam Therapeutics MEX:BEAM 64 Momentum Rank is 4 as of Sep. 07, 2026, which is 33% below its 10-year median of 6.00. GuruFocus rates MEX:BEAM with a GF Score™ of 64/100 and a GF Value™ of MXN425.92 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Beam Therapeutics has the Momentum Rank of 4.

Momentum Rank measures the strength and persistence of a stock's price movement over time, rated on a scale of 1 to 10.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

A higher score reflects strong price momentum and indicates greater potential for superior performance. Conversely, a lower score indicates that momentum is either too high or too low, and stocks tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Beam Therapeutics Momentum Rank Related Terms

MEX:BEAM vs MBX, ARQT, CLDX: Momentum Rank Comparison

For the Biotechnology subindustry, Beam Therapeutics's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Beam Therapeutics Momentum Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Beam Therapeutics's Momentum Rank distribution charts can be found below:

* The bar in red indicates where Beam Therapeutics's Momentum Rank falls into.


MEX:BEAM
64GF Score
Beam Therapeutics Inc MEX:BEAM
Momentum Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Momentum Rank →
What does a Momentum Rank of 4 mean?
Beam Therapeutics (MEX:BEAM) has a Momentum Rank of 4 as of Sep. 07, 2026. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Beam Therapeutics and its competitors. This is 33% below median its historical median of 6.00. Over the past decade, Beam Therapeutics' Momentum Rank has ranged from 4.00 to 8.00.
Is Beam Therapeutics' Momentum Rank too high?
Beam Therapeutics' current Momentum Rank of 4 is 33% below median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 8.00. Overall, Beam Therapeutics has a GF Score™ of 64/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Beam Therapeutics' Momentum Rank compare to MBX and ARQT?
Beam Therapeutics' Momentum Rank of 4 can be compared against companies in the Biotechnology industry. Historically, Beam Therapeutics' own Momentum Rank has ranged from 4.00 to 8.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Momentum Rank for a Biotechnology company?
A good Momentum Rank depends on the Biotechnology industry context. However, Momentum Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Momentum Rank mean?
A high Momentum Rank can signal that a stock is expensive relative to its fundamentals. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Beam Therapeutics and its competitors. Beam Therapeutics's current Momentum Rank is 4, which is 33% below median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beam Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Beam Therapeutics (MEX:BEAM) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN425.92, compared to a current price of MXN500.00 — trading 17.4% above its estimated fair value. The current Momentum Rank is 4, which is 33% below median its 10-year median of 6.00. Beam Therapeutics' overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Momentum Rank calculated?
Momentum Rank is calculated from a company's financial statements. For Beam Therapeutics (MEX:BEAM), the current Momentum Rank is 4 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beam Therapeutics (MEX:BEAM) Overvalued in 2026?

Based on GuruFocus' analysis, Beam Therapeutics stock appears to be overvalued. The current stock price of MXN500.00 is trading 17.4% above its estimated GF Value™ of MXN425.92. GuruFocus considers Beam Therapeutics to be Modestly Overvalued.

Key valuation signals for MEX:BEAM:

  • Momentum Rank: 4 (33% below median its 10-year median of 6.00)
  • GF Value™: MXN425.92 vs. price of MXN500.00 (17.4% above fair value)
  • GF Score™: 64/100 with 4 warning signs

No single metric tells the full story. See the MEX:BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beam Therapeutics Business Description

Other Exchanges BEAM:USA
Address 238 Main Street, Cambridge, MA, USA, 02142
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
64GF Score

Get the complete analysis for MEX:BEAM

Momentum Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN500.00
Price
MXN425.92
GF Value